(Q37853354)

24 August 2017

1 reference

title

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review (English)

1 reference

24 August 2017

0 references

0 references

1 reference

Laurent Peyrin-Biroulet

series ordinal

3

object named as

Laurent Peyrin-Biroulet

1 reference

24 August 2017

William Jeffery Sandborn

series ordinal

2

object named as

William J Sandborn

1 reference

24 August 2017

1

Vincent Billioud

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

The American Journal of Gastroenterology

24 August 2017

published in

1 reference

24 August 2017

volume

106

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

674-684

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Safety and efficacy of adalimumab in pediatric patients with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Adalimumab treatment in children with refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

The potential for disease modification in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.60

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.60

1 reference

24 August 2017

1 reference